arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

enGene Therapeutics Inc.

ENGN Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$1.85
Today
as of Jul 22, 16:48 ET
Last 30 days +14.20% Jun 12 → Jul 22
$1.60 $1.69 $1.77 $1.86 $1.95 Jun 12 Jun 22 Jun 29 Jul 08 Jul 15 Jul 22
Open
$1.71
High
$1.74
Low
$1.61
Volume
$952,504
Avg Vol
$829,728
Mkt Cap
$117M
P/E (TTM)
1.08
Beta
—
52w High
$12.25
52w Low
$1.40
Div Yield
—
Shares Out
$67M

Recent Press Releases & News last 60 days · 3 items

Jul 16 · 12:00 PR Business Wire
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Jun 16 · 09:08 BioPharma Dive
Neumora depression drug fails; EnGene to cut 50% of staff
Jun 15 · 13:00 PR Business Wire
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

Overview

52-week range
$1.40
$12
4% of range
Avg surprise (last 1)
-2.0%
Avg reaction (last 1)
+0.9%
100% positive
Latest IV / EM
47%
EM ±10.8% · $2 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.51$1.94$4.40$6.85$9.30 Actual $9.30Actual $8.55Actual $0.46Actual $0.38Actual $0.32Actual $0.48Actual $0.51Actual $-0.51Est $-0.50Actual $0.44 AprJulJanAprJulJanAprApr/2025Jan
Revenue vs Net Income Revenue Net income
$-30M$-26M$-22M$-19M$-15M Apr 24Jul 24Jan 25Apr 25Jul 25Jan 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Sat Jan 31, 2026Jan 2026 $0.44 — — — — financials
Thu Jun 12, 2025Apr/2025 $-0.51 $-0.50 -2.0% — +0.9% earnings
Wed Apr 30, 2025Apr 2025 $0.51 — — — — financials
Fri Jan 31, 2025Jan 2025 $0.48 — — — — financials
Wed Jul 31, 2024Jul 2024 $0.32 — — — — financials
Tue Apr 30, 2024Apr 2024 $0.38 — — — — financials
Wed Jan 31, 2024Jan 2024 $0.46 — — — — financials
Mon Jul 31, 2023Jul 2023 $8.55 — — — — financials
Sun Apr 30, 2023Apr 2023 $9.30 — — — — financials

Financials

Income statement (quarterly)

MetricJan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-31M—$-30M$-27M$-27M—$-17M$-17M
Net income$-30M—$-29M$-26M$-25M—$-14M$-15M
EPS (diluted)$0.44—$0.57$0.51$0.48—$0.32$0.38

Balance sheet (quarterly)

MetricJan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024
Cash & equivalents$37M$50M$33M$58M$62M$173M$258M$265M
Inventory————————
Total current assets$289M$201M$211M$228M$222M$247M$263M$270M
Total assets$337M$221M$246M$267M$286M$311M$267M$274M
Long-term debt————————
Total liabilities$56M$54M$45M$39M$36M$39M$37M$31M
Total equity$282M$168M$201M$227M$250M$273M$230M$243M

Implied volatility — last 90 days

39%322%604%887%1169% Jun 06 — IV 145% · EM ±25.7%Jun 07 — IV 330% · EM ±45.7%Jun 08 — IV 413% · EM ±54.5%Jun 09 — IV 358% · EM ±44.9%Jun 10 — IV 476% · EM ±56.2%Jun 11 — IV 441% · EM ±48.8%Jun 12 — IV 573% · EM ±58.6%Jun 15 — IV 469% · EM ±33.9%Jun 16 — IV 580% · EM ±34.3%Jun 17 — IV 1170% · EM ±48.9%Jun 19 — IV 39% · EM ±8.7%Jun 22 — IV 43% · EM ±8.9%Jun 23 — IV 43% · EM ±8.9%Jun 30 — IV 50% · EM ±8.7%Jul 06 — IV 94% · EM ±13.1%Jul 07 — IV 118% · EM ±15.6%Jul 08 — IV 86% · EM ±10.8%Jul 09 — IV 91% · EM ±10.8%Jul 14 — IV 333% · EM ±24.1%Jul 15 — IV 401% · EM ±23.7%Jul 20 — IV 45% · EM ±10.7%Jul 21 — IV 45% · EM ±10.4%Jul 22 — IV 47% · EM ±10.8%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,162.23-0.1%
JNJ
Johnson & Johnson
$601.7B $255.02-0.2%
ABBV
AbbVie Inc.
$447.7B $256.20+1.1%
MRK
Merck & Company, Inc.
$307.2B $127.47-0.0%
PM
Philip Morris International Inc
$300.4B $195.00+0.3%
NVS
Novartis AG
$293.4B $152.73-0.2%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in